share_log

8-K: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024

8-K: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024

8-K：百时美施贵宝公布2024年第三季度财务业绩
美股SEC公告 ·  10/31 19:55

Moomoo AI 已提取核心信息

On October 31, 2024, Bristol-Myers Squibb Company (BMS) released its financial results for the third quarter of 2024. The company reported revenues of $11.9 billion, marking an 8% increase compared to the same period in the previous year, with a notable 10% increase when adjusted for foreign exchange impacts. The growth was primarily driven by the company's Growth Portfolio, which includes products like Reblozyl, Breyanzi, Camzyos, and Opdualag. U.S. revenues rose by 9% to $8.2 billion, while international revenues saw a 7% increase to $3.7 billion. GAAP earnings per share (EPS) were reported at $0.60, while non-GAAP EPS stood at $1.80. The company also highlighted the U.S. approval of Cobenfy, a new treatment for schizophrenia, and raised its revenue guidance for 2024 to approximately 5%, with non-GAAP EPS estimates increased to a range of $0.75 to $0.95. The financial report included reconciliations between non-GAAP financial measures and comparable GAAP financial measures, with reasons for presenting such non-GAAP financial measures.
On October 31, 2024, Bristol-Myers Squibb Company (BMS) released its financial results for the third quarter of 2024. The company reported revenues of $11.9 billion, marking an 8% increase compared to the same period in the previous year, with a notable 10% increase when adjusted for foreign exchange impacts. The growth was primarily driven by the company's Growth Portfolio, which includes products like Reblozyl, Breyanzi, Camzyos, and Opdualag. U.S. revenues rose by 9% to $8.2 billion, while international revenues saw a 7% increase to $3.7 billion. GAAP earnings per share (EPS) were reported at $0.60, while non-GAAP EPS stood at $1.80. The company also highlighted the U.S. approval of Cobenfy, a new treatment for schizophrenia, and raised its revenue guidance for 2024 to approximately 5%, with non-GAAP EPS estimates increased to a range of $0.75 to $0.95. The financial report included reconciliations between non-GAAP financial measures and comparable GAAP financial measures, with reasons for presenting such non-GAAP financial measures.
2024年10月31日，施贵宝公司（BMS）发布了2024年第三季度的财务业绩。公司报告的营业收入为$119亿，较去年同期增长8%，考虑到汇率期货影响，实际增长了10%。增长主要由公司的成长组合驱动，其中包括Reblozyl、Breyanzi、Camzyos和Opdualag等产品。美国营业收入增长了9%，达到$82亿，而国际营业收入增长了7%，达到$37亿。按照美国通用会计准则，每股收益（EPS）为$0.60，而非美国通用会计准则的每股收益为$1.80。公司还强调了Cobenfy获得美国批准，这是一种用于治疗精神分裂症的新疗法，并将其2024年的营收指导提高到约5%，非美国通用会计准则的EPS预估提升至$0.75至$0.95的区间。财务报告包括非美国通用会计准则财务指标与可比美国通用会计准则财务指标之间的调和，以及为呈现此类非美国通用会计准则财务指标而提出的原因。
2024年10月31日，施贵宝公司（BMS）发布了2024年第三季度的财务业绩。公司报告的营业收入为$119亿，较去年同期增长8%，考虑到汇率期货影响，实际增长了10%。增长主要由公司的成长组合驱动，其中包括Reblozyl、Breyanzi、Camzyos和Opdualag等产品。美国营业收入增长了9%，达到$82亿，而国际营业收入增长了7%，达到$37亿。按照美国通用会计准则，每股收益（EPS）为$0.60，而非美国通用会计准则的每股收益为$1.80。公司还强调了Cobenfy获得美国批准，这是一种用于治疗精神分裂症的新疗法，并将其2024年的营收指导提高到约5%，非美国通用会计准则的EPS预估提升至$0.75至$0.95的区间。财务报告包括非美国通用会计准则财务指标与可比美国通用会计准则财务指标之间的调和，以及为呈现此类非美国通用会计准则财务指标而提出的原因。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    渤健公司
    BIIB
    -- 151.310
    Organon & Co
    OGN
    -- 15.060
    赛诺菲安万特
    SNY
    -- 48.730
    辉瑞
    PFE
    -- 26.620
    诺华制药
    NVS
    -- 98.390

    解锁榜首股票